Volume 97, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Pakistan has a high prevalence of hepatitis C virus (HCV) infection, estimated at 4.9% (2,290/46,843) in the 2007 national HCV seroprevalence survey. We used data from this survey to assess the importance of risk factor associations with HCV prevalence in Pakistan. Exposures were grouped as community (going to the barbers, sharing smoking equipment, having an ear/nose piercing, tattoo, or acupuncture), healthcare (ever having hemodialysis, blood transfusion, or ≥ 5 injections in the last year), demographic (marital status and age), and socio-economic (illiterate or laborer). We used mutually adjusted multivariable regression analysis, stratified by sex, to determine associations with HCV infection, their population attributable fraction, and how risk of infection accumulates with multiple exposures. Strength of associations was assessed using adjusted odds ratios (aOR). Community [aOR females 1.5 (95% confidence interval [CI]: 1.2, 1.8); males 1.2 (1.1, 1.4)] and healthcare [females 1.4 (1.2, 1.6); males 1.2 (1.1, 1.4)] exposures, low socio-economic status [females 1.6 (1.3, 1.80); males 1.3 (1.2, 1.5)], and marriage [females 1.5 (1.2, 1.9); males 1.4 (1.1, 1.8)] were associated with increased HCV infection. Among married women, the number of children was associated with an increase in HCV infection; linear trend aOR per child 1.06 (1.01, 1.11). Fewer infections could be attributed to healthcare exposures (females 13%; males 6%) than to community exposures (females 25%; males 9%). Prevalence increased from 3% to 10% when cumulative exposures increased from 1 to ≥ 4 [aOR per additional exposure for females 1.5 (1.4, 1.6); males 1.2 (1.2, 1.3)]. A combination of community, healthcare, and other factors appear to drive the Pakistan HCV epidemic, highlighting the need for a comprehensive array of prevention strategies.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, DuCros P, Ford N, , 2013. Viral hepatitis and the global burden of disease: a need to regroup. J Viral Hepat 20: 600601. [Google Scholar]
  2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385: 117171. [Google Scholar]
  3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H, , 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61: S45S57. [Google Scholar]
  4. De Angelis D, Sweeting M, Ades A, Hickman M, Hope V, Ramsay M, , 2009. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat Methods Med Res 18: 361379. [Google Scholar]
  5. McDonald SA, Hutchinson SJ, Schnier C, McLeod A, Goldberg DJ, , 2014. Estimating the number of injecting drug users in Scotland’s HCV-diagnosed population using capture-recapture methods. Epidemiol Infect 142: 200207. [Google Scholar]
  6. Thursz M, Fontanet A, , 2014. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 11: 2835. [Google Scholar]
  7. Averhoff FM, Glass N, Holtzman D, , 2012. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 55 (Suppl 1): S10S15. [Google Scholar]
  8. Reker C, Islam KM, , 2014. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis 25: 104106. [Google Scholar]
  9. Paez Jimenez A, 2009. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One 4: e7193. [Google Scholar]
  10. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L, , 2010. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006–2008. J Gastrointestin Liver Dis 19: 373379. [Google Scholar]
  11. El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG, , 2015. A comprehensive hepatitis C virus risk factors meta-analysis (1989–2013): do they differ in Egypt? Liver Int 35: 489501. [Google Scholar]
  12. Habib M , 2001. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 33: 248253. [Google Scholar]
  13. Stvilia K, Tsertsvadze T, Sharvadze L, Aladashvili M, del Rio C, Kuniholm MH, Nelson KE, , 2006. Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T’bilisi, Republic of Georgia. J Urban Health 83: 289298. [Google Scholar]
  14. Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P, Bansal M, , 2012. Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol 31: 232236. [Google Scholar]
  15. Khattak MN, Akhtar S, Mahmud S, Roshan TM, , 2008. Factors influencing hepatitis C virus sero-prevalence among blood donors in north west Pakistan. J Public Health Policy 29: 207225. [Google Scholar]
  16. Janjua NZ, Hamza HB, Islam M, Tirmizi SF, Siddiqui A, Jafri W, Hamid S, , 2010. Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. J Viral Hepat 17: 317326. [Google Scholar]
  17. Ahmed F, Irving WL, Anwar M, Myles P, Neal KR, , 2012. Prevalence and risk factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan: most infections remain unexplained. A cross-sectional study. Epidemiol Infect 140: 716723. [Google Scholar]
  18. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU, , 2010. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J 16 (Suppl): S15S23. [Google Scholar]
  19. World Health Organization, 2016. Combating Hepatitis B and C to Reach Elimination by 2030. Available at: www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/.
  20. Centers for Disease Control and Prevention, 2012. Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001–2012. MMWR Morb Mortal Wkly Rep 61: 545549. [Google Scholar]
  21. Gvinjilia L, 2016. National progress toward hepatitis C elimination - Georgia, 2015–2016. MMWR Morb Mortal Wkly Rep 65: 11321135. [Google Scholar]
  22. The World Bank, 2014. Health Expenditure, Total (% of GDP). Available at: data.worldbank.org/indicator/SH.XPD.TOTL.ZS.
  23. Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E, , 2014. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 109: 20532059. [Google Scholar]
  24. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K, , 2014. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 174: 19741981. [Google Scholar]
  25. Turner KM, 2011. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106: 19781988. [Google Scholar]
  26. Vickerman P, Page K, Maher L, Hickman M, , 2014. Commentary on Nolan et al. (2014): opiate substitution treatment and hepatitis C virus prevention: building an evidence base? Addiction 109: 20602061. [Google Scholar]
  27. White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L, , 2014. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust 201: 326329. [Google Scholar]
  28. Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, McAllister G, Gunson R, Hutchinson SJ, , 2014. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One 9: e104515. [Google Scholar]
  29. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M, , 2011. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 54: 11371144. [Google Scholar]
  30. Martin NK , 2013. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58: 15981609. [Google Scholar]
  31. World Health Organization, 2015. WHO Guideline on the Use of Safety-Engineered Syringes for Intramuscular, Intradermal and Subcutaneous Injection in Health Care Settings. Available at: apps.who.int/iris/bitstream/10665/250144/1/9789241549820-eng.pdf.
  32. Pepin J, Abou Chakra CN, Pepin E, Nault V, Valiquette L, , 2014. Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010. PLoS One 9: e99677. [Google Scholar]
  33. Druyts EF, Rachlis BS, Lima VD, Harvard SS, Zhang W, Brandson EK, Strathdee SA, Montaner JS, Hogg RS, , 2009. Mortality is influenced by locality in a major HIV/AIDS epidemic. HIV Med 10: 274281. [Google Scholar]
  34. Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, Hart C, , 2010. Amphetamine-group substances and HIV. Lancet 376: 458474. [Google Scholar]
  35. Cooper DA, , 2008. Life and death in the cART era. Lancet 372: 266267. [Google Scholar]
  36. Shahid APA, Memon AA, , 2012. Knowledge and educational intervention pertaining to viral hepatitis in adolescent male students of urban and rural Sindh, Pakistan. Journal of the Dow University of Health Sciences Karachi 6: 6669. [Google Scholar]
  37. Shahid ANS, Memon AA, , 2013. Insight and educational intervention concerning hepatitis among roadside barbers and their clients in Karachi, Pakistan. J Infect Dev Ctries 7: 125129. [Google Scholar]
  38. Krishanani MK, Qidwai W, Ali BS, Khuwaja AK, , 2010. Educational intervention among barbers about liver cancer-inducing viruses: a pilot study from a developing country. J Cancer Educ 25: 632636. [Google Scholar]
  39. World Health Organization, 2001. Hepatitis C Assays: Operational Characteristics (Phase I): Report 1. Available at: apps.who.int/iris/bitstream/10665/66829/1/WHO_BCT_BTS_01.2.pdf.
  40. Clarke L, , 2001. Shīʻite Heritage: Essays on Classical and Modern Traditions. Global Academic Publishing. Available at: https://books.google.co.uk/books?id=kUp098iHgNwC&pg=PA386&redir_esc=y#v=onepage&q&f=false. Accessed June 1, 2001.
  41. Blank J, , 2001. Mullahs on the Mainframe: Islam and Modernity among the Daudi Bohras. University of Chicago Press. https://books.google.co.uk/books?id=r_FExBRnC3YC&pg=PA93&dq=matam&hl=en&sa=X&ei=DTf4UPf1IsnMrQff2YGgDQ&redir_esc=y#v=onepage&q=matam&f=false. Accessed April 15, 2001.
  42. Laaksonen M, , 2010. Population Attributable Fraction (PAF) in Epidemiologic Follow-up Studies. Available at: tampub.uta.fi/bitstream/handle/10024/66625/978-951-44-8149-9.pdf;sequence=1.
  43. Idrees M, Lal A, Naseem M, Khalid M, , 2008. High prevalence of hepatitis C virus infection in the largest province of Pakistan. J Dig Dis 9: 95103. [Google Scholar]
  44. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L, , 2011. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571583. [Google Scholar]
  45. Akhtar AMKM, Ijaz T, Iqbal Z, Rana MY, Maqbool A, Rehman A, , 2013. Seroprevalence and determinants of hepatitis C virus infection in blood donors of Lahore, Pakistan. Pak J Zool 45: 17. [Google Scholar]
  46. Kandeel AM, Talaat M, Afifi SA, El-Sayed NM, Abdel Fadeel MA, Hajjeh RA, Mahoney FJ, , 2012. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. BMC Infect Dis 12: 294. [Google Scholar]
  47. Mohsen A, 2015. Hepatitis C virus acquisition among Egyptians: analysis of a 10-year surveillance of acute hepatitis C. Trop Med Int Health 20: 8997. [Google Scholar]
  48. Ghabrah TM, Stickland GT, Tsarev S, Yarbough P, Farci P, Engle R, Emerson S, Purcell R, , 1995. Acute viral hepatitis in Saudi Arabia: seroepidemiological analysis, risk factors, clinical manifestations, and evidence for a sixth hepatitis agent. Clin Infect Dis 21: 621627. [Google Scholar]
  49. Aziz S, Khanani R, Noorulain W, Rajper J, , 2010. Frequency of hepatitis B and C in rural and periurban Sindh. J Pak Med Assoc 60: 853857. [Google Scholar]
  50. Hashmi A, Saleem K, Soomro JA, , 2010. Prevalence and factors associated with hepatitis C virus seropositivity in female individuals in Islamabad, Pakistan. Int J Prev Med 1: 252256. [Google Scholar]
  51. Masood ZMJ, Khan RA, Rehman S, , 2005. Screening for hepatitis B & C: a routine preoperative investigation? Pak J Med Sci 21: 455459. [Google Scholar]
  52. Sami S, Korejo R, Bhutta SZ, , 2009. Prevalence of hepatitis B and C: a Jinnah Postgraduate Medical Centre experience. J Obstet Gynaecol Res 35: 533538. [Google Scholar]
  53. Taseer IU, Ishaq F, Hussain L, Safdar S, Mirbahar AM, Faiz SA, , 2010. Frequency of anti-HCV, HBsAg and related risk factors in pregnant women at Nishtar Hospital, Multan. J Ayub Med Coll Abbottabad 22: 1316. [Google Scholar]
  54. Taseer IUIF, Hussain L, Safdar S, Mirbahar AM, Faiz SA, , 2010. Frequency of anti-HCV, HBsAg and related risk factors in pregnant women at Nishtar Hospital, Multan. J Ayub Med Coll Abbottabad 22: 1316. [Google Scholar]
  55. Luby SP, Qamruddin K, Shah AA, Omair A, Pahsa O, Khan AJ, McCormick JB, Hoodbhouy F, Fisher-Hoch S, , 1997. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect 119: 349356. [Google Scholar]
  56. Bari A, Akhtar S, Rahbar MH, Luby SP, , 2001. Risk factors for hepatitis C virus infection in male adults in Rawalpindi-Islamabad, Pakistan. Trop Med Int Health 6: 732738. [Google Scholar]
  57. Pasha O, Luby SP, Khan AJ, Shah SA, McCormick JB, Fisher-Hoch SP, , 1999. Household members of hepatitis C virus-infected people in Hafizabad, Pakistan: infection by injections from health care providers. Epidemiol Infect 123: 515518. [Google Scholar]
  58. Jafri W, Jafri N, Yakoob J, Islam M, Tirmizi SF, Jafar T, Akhtar S, Hamid S, Shah HA, Nizami SQ, , 2006. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis 6: 101. [Google Scholar]
  59. Janjua NZ, Mahmood B, Imran Khan M, , 2014. Does knowledge about bloodborne pathogens influence the reuse of medical injection syringes among women in Pakistan? J Infect Public Health 7: 345355. [Google Scholar]
  60. Akahane Y, 1994. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 120: 748752. [Google Scholar]
  61. Goto M, Fujiyama S, Kawano S, Taura Y, Sato S, Sato T, Akahoshi M, , 1994. Intrafamilial transmission of hepatitis C virus. J Gastroenterol Hepatol 9: 1318. [Google Scholar]
  62. Kao JH, Chen PJ, Yang PM, Lai MY, Sheu JC, Wang TH, Chen DS, , 1992. Intrafamilial transmission of hepatitis C virus: the important role of infections between spouses. J Infect Dis 166: 900903. [Google Scholar]
  63. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T, , 2006. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. World J Gastroenterol 12: 70257028. [Google Scholar]
  64. Khan UR, Janjua NZ, Akhtar S, Hatcher J, , 2008. Case-control study of risk factors associated with hepatitis C virus infection among pregnant women in hospitals of Karachi-Pakistan. Trop Med Int Health 13: 754761. [Google Scholar]
  65. Gatrad AR, Ray M, Sheikh A, , 2004. Hindu birth customs. Arch Dis Child 89: 10941097. [Google Scholar]
  66. Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA, , 2011. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Virol J 8: 466. [Google Scholar]
  67. Qazi HA, Saleem K, Mujtaba I, Hashmi A, Soomro JA, , 2010. Prevalence and factors associated with HCV (hepatitis C virus) seropositivity in Islamabad, Pakistan. Acta Med Iran 48: 394398. [Google Scholar]
  68. Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM, , 2011. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV− mothers: a meta-analysis. Arch Gynecol Obstet 283: 255260. [Google Scholar]
  69. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ, , 2014. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 59: 765773. [Google Scholar]
  70. Raza AWA, Amin S, Ejaz SZ, Ashraf U, Majeed U, Aziz S, , 2013. Effects of counseling and education to patients presenting with hepatitis at a tertiary care hospital. Pak J Med Res 52: 811. [Google Scholar]
  71. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR, , 2006. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 41: 194200. [Google Scholar]
  72. Crothers K, 2009. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev 21: 4053. [Google Scholar]
  73. Guerra J, Garenne M, Mohamed MK, Fontanet A, , 2012. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 19: 560567. [Google Scholar]
  74. Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T, , 2014. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompressed Cirrhosis: Preliminary Results of a Prospective, Multicenter Study. American Association for the Study of Liver Diseases (AASLD) Liver Meeting. November 7–12, Boston (Abstract 239).
  75. Feeney ER, Chung RT, , 2014. Antiviral treatment of hepatitis C. BMJ 348: g3308. [Google Scholar]
  76. Chaudhry A, , 2014. Sovaldi – ‘miracle’ hepatitis C oral drug gets official nod. Dawn.
  77. Arankalle A, Chobe P, Banerjee K, , 1992. Hepatitis C virus in Pune, India. J Assoc Physicians India 40: 562563. [Google Scholar]
  78. Chaudhry A, , 2014. Sovaldi - ‘Miracle’ Hepatitis C Oral Drug gets Official Nod. Dawn. Available at: https://www.dawn.com/news/1145916.

Data & Media loading...

Supplemental Material

  • Received : 10 Jan 2017
  • Accepted : 04 Jul 2017
  • Published online : 16 Oct 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error